Learn together
Find the rooms where new evidence becomes better practice. Preview upcoming sessions, active members, and the discussions worth joining.

The ORBITA-CTO trial represents a significant advancement in the understanding of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) for relieving angina. By employing a rigorous randomized, double-blind, placebo-controlled design, the study successfully differentiated between the placebo effect and the true therapeutic benefits of CTO PCI, showing it leads to marked improvements in angina symptom reduction over a 24-week follow-up period.
With David J. Cohen and 16 experts
3 key takeaways
The trial demonstrated that CTO PCI improves angina symptoms beyond placebo, particularly reducing angina frequency.
Patients undergoing CTO PCI reported significantly more days free of angina compared to those receiving a placebo.
The findings support a symptom-driven approach to CTO PCI in carefully selected patients, reinforcing the necessity of a heart team approach.
Find your room
Continue the conversation
Where leading experts discuss new research and decide what matters.
Explore Journal Clubs